Samuel L Davis

US Patent:

6433143, Aug 13, 2002

Filed:

Sep 16, 1999

Appl. No.:

08/817318

Inventors:

Samuel Davis - New York NY
Joanne Bruno - Bloomingdale NJ
Mitchell Goldfarb - River Edge NJ
Thomas H. Aldrich - Ossining NY
Peter C. Maisonpierre - Croton NY
Czeslaw Radziejewski - Somers NY
Pamela F. Jones - Leeds, GB
George D. Yancopoulos - Yorktown Heights NY

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

C07K 1452

US Classification:

530351, 530402, 435 697, 435471, 435 712, 435325, 4352523, 43525411, 4353201

Abstract:

The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptor body, which specifically binds a human TIE-2 ligand. The invention also provides an antibody that specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.

US Patent:

6441137, Aug 27, 2002

Filed:

Nov 9, 2000

Appl. No.:

09/709188

Inventors:

Samuel Davis - New York NY
George D. Yancopoulos - Yorktown Heights NY

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

C12P 2104

US Classification:

530350, 435 697

Abstract:

The present invention provides for a modified TIE-2 ligand which has been altered by addition, deletion or substitution of one or more amino acids, or by way of tagging, with for example, the Fc portion of human IgG-1, but which retains its ability to bind the TIE-2 receptor. The invention further provides for a modified TIE-2 ligand which is a chimeric TIE-2 ligand comprising at least a portion of a first TIE-2 ligand and a portion of a second TIE-2 ligand which is different from the first. In a specific embodiment, the invention further provides for a chimeric TIE ligand comprising at least a portion of TIE-2 Ligand-1 and a portion of TIE-2 Ligand-2. In addition the present invention provides for isolated nucleic acid molecule encoding the modified TIE-2 ligands described. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE receptor, a method of blocking the growth or differentiation of a cell expressing the TIE receptor and a method of attenuating or preventing tumor growth in a human.

US Patent:

6602683, Aug 5, 2003

Filed:

Apr 24, 1998

Appl. No.:

09/051994

Inventors:

Samuel Davis - New York NY
Nicholas W. Gale - Tarrytown NY
George D. Yancopoulos - Yorktown Heights NY

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

C12N 1500

US Classification:

435 691, 4353201, 435325, 536235, 530350

Abstract:

A novel ligand (Efl-6) that binds the Elk subfamily of Eph receptors is identified, and methods for making the soluble Elf-6 ligand in biologically active form is described. A cDNA clone encoding this novel protein enables production of the recombinant protein, which is useful to support neuronal and other eph receptor-bearing cell populations.

US Patent:

6627415, Sep 30, 2003

Filed:

Nov 18, 1999

Appl. No.:

09/442717

Inventors:

Samuel Davis - New York NY
George D. Yancopoulos - Yorktown Heights NY

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

C12N 1519

US Classification:

435 695, 530351, 536 235, 435 711, 435 712, 435471, 4353201, 435325, 4352523, 43525411

Abstract:

The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptorbody which specifically binds a human TIE-2 ligand. The invention also provides an antibody which specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention further provides for a ligandbody which specifically binds TIE-2 receptor. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth, differentiation or migration of cells expressing the TIE-2 receptor, including, but not limited to, hematopoietic precursor cells, a method of blocking the growth, differentiation or migration of cells expressing the TIE-2 receptor including, but not limited to, hematopoietic precursor cells, and a method of attenuating or preventing tumor growth in a human.

US Patent:

6645484, Nov 11, 2003

Filed:

Oct 12, 2000

Appl. No.:

09/689020

Inventors:

Samuel Davis - New York NY
JoAnne Bruno - Bloomingdale NJ
Mitchell Goldfarb - River Edge NJ
Thomas H. Aldrich - Ossining NY
Peter C. Maisonpierre - Croton NY
Czeslaw Radziejewski - N. White Plains NY
Pamela F. Jones - Fairfield CT
George D. Yancopoulos - Yorktown Heights NY

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

A61K 3819

US Classification:

424 851, 514 2, 514 8, 514 12

Abstract:

The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptor body which specifically binds a human TIE-2 ligand. The invention also provides an antibody which specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.

US Patent:

6825008, Nov 30, 2004

Filed:

Aug 21, 2002

Appl. No.:

10/225060

Inventors:

Samuel Davis - New York NY
George D. Yancopoulos - Yorktown Heights NY

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

G12P 2106

US Classification:

435 691, 536 234, 4353201, 4352523, 435325, 435455

Abstract:

The present invention provides for a modified TIE-2 ligand which has been altered by addition, deletion or substitution of one or more amino acids, or by way of tagging, with for example, the Fc portion of human IgG-1, but which retains its ability to bind the TIE-2 receptor. The invention further provides for a modified TIE-2 ligand which is a chimeric TIE-2 ligand comprising at least a portion of a first TIE-2 ligand and a portion of a second TIE-2 ligand which is different from the first. In a specific embodiment, the invention further provides for a chimeric TIE ligand comprising at least a portion of TIE-2 Ligand-1 and a portion of TIE-2 Ligand-2. In addition the present invention provides for isolated nucleic acid molecule encoding the modified TIE-2 ligands described. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE receptor, a method of blocking the growth or differentiation of a cell expressing the TIE receptor and a method of attenuating or preventing tumor growth in a human.

US Patent:

7008781, Mar 7, 2006

Filed:

Dec 23, 1999

Appl. No.:

09/868677

Inventors:

Samuel Davis - New York NY, US
Nicholas W. Gale - Tarrytown NY, US
George D. Yancopoulos - Yorktown Heights NY, US
Neil Stahl - Carmel NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

C12N 15/18
C12N 15/62

US Classification:

435 697, 435348, 4352542, 43525233, 435360, 4353651, 4353201, 536 235, 530399, 514 2, 514 12, 4241341, 4241921

Abstract:

Novel fusion polypeptide ligands that bind Eph family receptors or the Tie-2 receptor are identified, and methods for making the fusion polypeptide ligands in biologically active form are described. Nucleic acids encoding these novel fusion polypeptide ligands enable production of the fusion polypeptide ligands. The method of making the nucleic acids and the fusion polypeptide ligands is broadly applicable to the production of polypeptide ligands in general, resulting in improved affinity and/or increased activity of the ligand when compared to its native form.

US Patent:

7045302, May 16, 2006

Filed:

Mar 4, 2005

Appl. No.:

11/073120

Inventors:

Samuel Davis - New York NY, US
George D. Yancopoulos - Yorktown Heights NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

A61K 39/00
C07K 16/00
G01N 33/35

US Classification:

435 71, 4241921, 4241931, 4241851, 5303911

Abstract:

The present invention provides for a modified TIE-2 ligand 2 which has been altered by addition, deletion or substitution of one or more amino acids, or by way of tagging, with for example, the Fc portion of human IgG-1, but which retains its ability to bind the TIE-2 receptor.